Skandinaviska Enskilda Banken AB publ Has $56.55 Million Stake in Pfizer Inc. (PFE)

Skandinaviska Enskilda Banken AB publ increased its position in Pfizer Inc. (NYSE:PFE) by 5.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,583,938 shares of the biopharmaceutical company’s stock after purchasing an additional 88,653 shares during the quarter. Skandinaviska Enskilda Banken AB publ’s holdings in Pfizer were worth $56,547,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the stock. Vanguard Group Inc. grew its stake in Pfizer by 2.3% in the second quarter. Vanguard Group Inc. now owns 418,639,111 shares of the biopharmaceutical company’s stock worth $14,062,088,000 after purchasing an additional 9,239,499 shares in the last quarter. Ameriprise Financial Inc. grew its stake in Pfizer by 4.4% in the third quarter. Ameriprise Financial Inc. now owns 59,844,024 shares of the biopharmaceutical company’s stock worth $2,136,189,000 after purchasing an additional 2,502,659 shares in the last quarter. Franklin Resources Inc. grew its stake in Pfizer by 0.9% in the second quarter. Franklin Resources Inc. now owns 46,167,213 shares of the biopharmaceutical company’s stock worth $1,550,754,000 after purchasing an additional 389,629 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in Pfizer by 4.8% in the second quarter. Dimensional Fund Advisors LP now owns 44,286,544 shares of the biopharmaceutical company’s stock worth $1,487,617,000 after purchasing an additional 2,028,313 shares in the last quarter. Finally, Fisher Asset Management LLC grew its stake in Pfizer by 3.2% in the third quarter. Fisher Asset Management LLC now owns 35,120,799 shares of the biopharmaceutical company’s stock worth $1,253,813,000 after purchasing an additional 1,085,437 shares in the last quarter. 70.06% of the stock is currently owned by institutional investors.

Shares of Pfizer Inc. (PFE) opened at $36.26 on Friday. Pfizer Inc. has a twelve month low of $31.67 and a twelve month high of $39.43. The company has a current ratio of 1.43, a quick ratio of 1.15 and a debt-to-equity ratio of 0.56. The company has a market capitalization of $216,140.00, a price-to-earnings ratio of 10.30, a PEG ratio of 2.02 and a beta of 0.94.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.62 EPS for the quarter, beating the consensus estimate of $0.56 by $0.06. Pfizer had a return on equity of 26.86% and a net margin of 40.55%. The firm had revenue of $13.70 billion during the quarter, compared to analyst estimates of $13.67 billion. During the same quarter in the prior year, the business posted $0.47 EPS. The business’s revenue for the quarter was up .6% compared to the same quarter last year. sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer declared that its board has initiated a stock repurchase plan on Monday, December 18th that permits the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization permits the biopharmaceutical company to purchase shares of its stock through open market purchases. Shares repurchase plans are often an indication that the company’s board of directors believes its shares are undervalued.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 1st. Stockholders of record on Friday, February 2nd will be issued a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a dividend yield of 3.75%. The ex-dividend date of this dividend is Thursday, February 1st. This is a positive change from Pfizer’s previous quarterly dividend of $0.32. Pfizer’s dividend payout ratio is currently 38.64%.

In related news, insider Alexander R. Mackenzie sold 6,750 shares of the company’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $37.00, for a total value of $249,750.00. Following the transaction, the insider now directly owns 103,458 shares of the company’s stock, valued at approximately $3,827,946. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Rady A. Johnson sold 8,000 shares of the company’s stock in a transaction on Friday, December 15th. The shares were sold at an average price of $37.07, for a total value of $296,560.00. Following the completion of the transaction, the executive vice president now directly owns 46,963 shares in the company, valued at $1,740,918.41. The disclosure for this sale can be found here. Corporate insiders own 0.06% of the company’s stock.

Several research analysts recently issued reports on PFE shares. Morningstar set a $38.00 price objective on Pfizer and gave the stock a “neutral” rating in a research note on Tuesday, January 30th. UBS Group set a $42.00 price objective on Pfizer and gave the stock a “buy” rating in a research note on Wednesday, January 31st. Nord/LB reissued a “neutral” rating on shares of Pfizer in a research note on Wednesday, December 27th. Zacks Investment Research upgraded Pfizer from a “hold” rating to a “buy” rating and set a $41.00 target price for the company in a report on Wednesday, January 24th. Finally, Sanford C. Bernstein set a $43.00 target price on Pfizer and gave the stock a “buy” rating in a report on Tuesday, January 30th. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have given a buy rating to the stock. Pfizer has an average rating of “Hold” and a consensus target price of $39.45.

WARNING: This story was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this story on another publication, it was copied illegally and reposted in violation of international copyright laws. The legal version of this story can be viewed at https://ledgergazette.com/2018/02/18/skandinaviska-enskilda-banken-ab-publ-has-56-55-million-stake-in-pfizer-inc-pfe.html.

Pfizer Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply